Melanoma Antibody (LHM 3): sc-53370
- Melanoma Antibody (LHM 3) is a mouse monoclonal IgG1 κ Melanoma antibody, cited in 1 publications, provided at 200 µg/ml
- raised against A 375P cell extract of human origin
- Melanoma Antibody (LHM 3) is recommended for detection of Melanoma of human origin by WB and IF
- Anti-Melanoma Antibody (LHM 3) is available conjugated to agarose for IP; HRP for WB, IHC(P) and ELISA; and to either phycoerythrin or FITC for IF, IHC(P) and FCM
- also available conjugated to Alexa Fluor® 488, Alexa Fluor® 546, Alexa Fluor® 594 or Alexa Fluor® 647 for WB (RGB), IF, IHC(P) and FCM, and for use with RGB fluorescent imaging systems, such as iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- also available conjugated to Alexa Fluor® 680 or Alexa Fluor® 790 for WB (NIR), IF and FCM; for use with Near-Infrared (NIR) detection systems, such as LI-COR®Odyssey®, iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for Melanoma Antibody (LHM 3) for WB applications. These reagents are now offered in bundles with Melanoma Antibody (LHM 3) (see ordering information below).
QUICK LINKS
SEE ALSO...
Melanoma Antibody (LHM 3) is a mouse monoclonal IgG1 kappa light chain antibody that detects Melanoma protein of human origin by western blotting (WB) and immunofluorescence (IF). Melanoma monoclonal antibody (LHM 3) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. Melanoma (LHM 3) antibody targets a protein crucial for cell proliferation and survival regulation, making Melanoma a significant therapeutic target in melanoma treatment. Melanoma (LHM 3) monoclonal antibody recognizes a protein primarily located in cell membranes, where Melanoma participates in signaling pathways controlling cell growth and differentiation. Understanding membrane localization is vital, as alterations can lead to aberrant signaling and contribute to melanoma′s aggressive nature. Epidemiological studies indicate that exposure to ultraviolet radiation is a major risk factor for developing melanoma, characterized by malignant neoplasms of melanocytes. These cells produce melanin, responsible for skin, hair, and eye color, and are predominantly found in moles. The four most common types of melanoma include superficial spreading melanomas, nodular melanomas, acral lentiginous melanomas, and lentigo malignas, each with distinct characteristics and clinical implications.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Melanoma Antibody (LHM 3) References:
- Fullerene (C60) immunoconjugates: interaction of water-soluble C60 derivatives with the murine anti-gp240 melanoma antibody. | Ashcroft, JM., et al. 2006. Chem Commun (Camb). 3004-6. PMID: 16832518
- Melanoma control: few answers, many questions. | Dunbar, R., et al. 2006. N Z Med J. 119: U2172. PMID: 16998573
- Images in clinical medicine. Plantar melanoma--a false vegetant wart. | De Giorgi, V. and Massi, D. 2006. N Engl J Med. 355: e13. PMID: 17005944
- Sentinel-node biopsy in melanoma. | Balch, CM. and Cascinelli, N. 2006. N Engl J Med. 355: 1370-1. PMID: 17005955
- Molecular mechanisms in melanoma. | Diaz-Cano, SJ. 2006. N Engl J Med. 355: 1395; author reply 1396. PMID: 17005965
- Blocking factors against leucocyte-dependent melanoma antibody in the sera of melanoma patients. | Murray, E., et al. 1977. Br J Cancer. 36: 7-14. PMID: 19029
- [Immunoscintigraphy with 99mTc marked melanoma antibody in patients with malignant melanoma]. | Rentsch, M., et al. 1989. Helv Chir Acta. 56: 11-3. PMID: 2777587
- Radioimmunoscintigraphy of ocular melanoma with 99mTc labelled cutaneous melanoma antibody fragments. | Bomanji, J., et al. 1987. Br J Ophthalmol. 71: 651-8. PMID: 2822079
- Replacement therapy in uncooperative patients with endocrine-deficiency states. | Fraser, AR. and Clark, F. 1979. Lancet. 1: 667. PMID: 85896
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Melanoma Antibody (LHM 3) | sc-53370 | 200 µg/ml | $322.00 | |||
Melanoma Antibody (LHM 3): m-IgG Fc BP-HRP Bundle | sc-526802 | 200 µg Ab; 10 µg BP | $361.00 | |||
Melanoma Antibody (LHM 3): m-IgG1 BP-HRP Bundle | sc-532175 | 200 µg Ab; 20 µg BP | $361.00 | |||
Melanoma Antibody (LHM 3) AC | sc-53370 AC | 500 µg/ml, 25% agarose | $424.00 | |||
Melanoma Antibody (LHM 3) HRP | sc-53370 HRP | 200 µg/ml | $322.00 | |||
Melanoma Antibody (LHM 3) FITC | sc-53370 FITC | 200 µg/ml | $336.00 | |||
Melanoma Antibody (LHM 3) PE | sc-53370 PE | 200 µg/ml | $349.00 | |||
Melanoma Antibody (LHM 3) Alexa Fluor® 488 | sc-53370 AF488 | 200 µg/ml | $364.00 | |||
Melanoma Antibody (LHM 3) Alexa Fluor® 546 | sc-53370 AF546 | 200 µg/ml | $364.00 | |||
Melanoma Antibody (LHM 3) Alexa Fluor® 594 | sc-53370 AF594 | 200 µg/ml | $364.00 | |||
Melanoma Antibody (LHM 3) Alexa Fluor® 647 | sc-53370 AF647 | 200 µg/ml | $364.00 | |||
Melanoma Antibody (LHM 3) Alexa Fluor® 680 | sc-53370 AF680 | 200 µg/ml | $364.00 | |||
Melanoma Antibody (LHM 3) Alexa Fluor® 790 | sc-53370 AF790 | 200 µg/ml | $364.00 |